When was N-of-One founded?

N-of-One was founded in 2008 and raised its 1st funding round 3 years after it was founded.

Where is N-of-One located?

N-of-One is headquartered in Lexington, United States.

How many employees does N-of-One have?

As of Jul 31, 2026, the latest employee count at N-of-One is 9.

Is N-of-One a funded company?

N-of-One is a funded company, having raised a total of $17.7M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 31, 2011.

When was the latest funding round of N-of-One?

N-of-One's latest funding was a $***** Series B round on Jan 18, 2017, with participation from 0 investor. Its primary sector is Healthcare IT. In United States, the Healthcare IT sector has seen $5.44B in funding in 2026 to date.

Where does N-of-One rank among its competitors?

N-of-One ranks 75th amongst 247 active competitors, of which 69 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Solid Biosciences, which secured $240M in Mar, 2026.

Who are the top competitors of N-of-One?

N-of-One's top competitors include MedGenome, Caris Life Sciences and Atrys. Among them, Solid Biosciences secured the most recent funding round in March, 2026.

N-of-One - 2026 Company Profile, Team, Funding & Competitors

Company Details

NGS analysis, interpretation, and reporting solutions for research and clinical applications. They provide end-to-end solutions for Next Generation Sequencing (NGS) data, catering to both research and clinical needs. Their offerings span secondary analysis, interpretation, and visualization, leveraging knowledge bases and pathway analysis. They offer cloud-based solutions, clinical decision support software, and professional clinical interpretation services. They support various applications including biomedical genomics, microbial genomics, single-cell sequencing, and translational research. Their services aid in biomarker identification, target discovery, and drug discovery. They offer solutions for oncology, hereditary diseases, and rare & undiagnosed diseases. They provide tools for variant analysis, data and pipeline management, and access to curated genomic data. They offer clinical testing solutions, knowledge bases, and services to improve test turnaround times and clinical reporting capabilities. They provide expert-curated content and professional interpretation services for molecular oncology labs. They offer software, databases, and services for researchers and clinicians in the fields of genomics and precision medicine.

Website: n-of-one.com
Social

Key Metrics

Founded Year

2008

Location

Lexington, United States

Stage

Acqui-Hired

Total Funding

$17.7M in 6 rounds

Latest Funding Round

Series B, Jan 18, 2017, $*****

Investors

Allumia Ventures & 4 more

Ranked

75^th among 247 active competitors

Employee Count

9 as on Jul 31, 2026

Similar Companies

MedGenome & 362 more

View N-of-One's full profile

N-of-One has raised a total funding of $17.7M over 6 rounds. Its first funding round was on Aug 31, 2011. N-of-One has 5 institutional investors.

Here is the list of recent funding rounds of N-of-One:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 18, 2017	4803886	Series B	8299970	5564670	8522423	1734431
Jul 21, 2016	5494029	Series B	9005378	9942109	7420598	Excel Venture Management & 1 more
Jan 07, 2016	6139580	Series B	1755098	3381677	1908166	2853083

Access funding benchmarks and valuations. Sign up today!

View details of N-of-One's funding rounds and investors

The founders of N-of-One is Jennifer Levin Carter.

Here are the details of N-of-One's key team members:

Jennifer Levin Carter: Founder, President & CMO of N-of-One.

View details of N-of-One's Founder profiles and Board Members

N-of-One's employee count trend

N-of-One has 9 employees as of Jul 26. Here is N-of-One's employee count trend over the years:

Uncover N-of-One's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of N-of-One include MedGenome, Caris Life Sciences and Atrys. Here is the list of Top 10 competitors of N-of-One, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
2nd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
3rd	Atrys 2007, Barcelona (Spain), Public	Provider of diagnostic and therapeutic services catering to cancer	-	ING, Europa & 4 others	64/100
4th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
5th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
6th	Repare Therapeutics 2016, Montreal (Canada), Acquired	Developer of targeted therapies to address the genetic alterations associated with selected tumors	$166M	Versant Ventures, Cowen & 13 others	60/100
7th	Exicure 2009, Skokie (United States), Public	developer of gene silencing & immunomodulatory drugs using spherical nucleic acid (SNA) technology	$72.3M	Abbott Biotech Ventures, Luye Pharma & 18 others	60/100
8th	Solid Biosciences 2014, Cambridge (United States), Public	Developer of gene therapy platform for Duchenne muscular dystrophy	$92.5M	Bain Capital Life Sciences, RA Capital Management ... & 18 others	60/100
9th	Exosome Diagnostics 2008, Boston (United States), Acquired	Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring	$119M	Forbion, NGN Capital & 7 others	60/100
10th	Precipio Diagnostics 1997, New Haven (United States), Public	Provider of cancer diagnostics and second opinion tools	$800K	Enhanced Capital, Ironwood Capital & 3 others	60/100
75th	N-of-One 2008, Lexington (United States), Acqui-Hired	NGS analysis, interpretation, and reporting solutions for research and clinical applications	$17.7M	Allumia Ventures, Philips Ventures & 3 others	39/100